Venetoclax-Rituximab in Chronic Lymphocytic Leukemia

被引：0
|
作者：
Copur, Mehmet S. [1 ]
Gauchan, Dron [1 ]
Crockett, David [1 ]
机构：
[1] Catholic Hlth Initiat, St Francis Canc Treatment Ctr, Grand Isl, NE 68803 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2018年 / 378卷 / 22期
关键词：
CHLORAMBUCIL; TRIALS;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2142 / +
页数：2
相关论文
共 50 条
  • [1] Venetoclax-Rituximab in Chronic Lymphocytic Leukemia REPLY
    Seymour, John F.
    Mobasher, Mehrdad
    Kater, Arnon P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22): : 2143 - +
  • [2] Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Seymour, J. F.
    Kipps, T. J.
    Eichhorst, B.
    Hillmen, P.
    D'Rozario, J.
    Assouline, S.
    Owen, C.
    Gerecitano, J.
    Robak, T.
    De la Serna, J.
    Jaeger, U.
    Cartron, G.
    Montillo, M.
    Humerickhouse, R.
    Punnoose, E. A.
    Li, Y.
    Boyer, M.
    Humphrey, K.
    Mobasher, M.
    Kater, A. P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (12): : 1107 - 1120
  • [3] Demyelinating Polyradiculoneuropathy in Chronic Lymphocytic Leukemia: A Case Report on BTKis versus Venetoclax-Rituximab
    Cellini, Alessandro
    Visentin, Andrea
    Salvalaggio, Alessandro
    Cacciavillani, Mario
    Ferrari, Sergio
    Briani, Chiara
    HEMATO, 2024, 5 (01): : 19 - 25
  • [4] MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab Combination Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (01) : 15 - 16
  • [5] Leukemia cutis in accelerated chronic lymphocytic leukemia: successful treatment with venetoclax and rituximab
    Robak, Ewa
    Jesionek-Kupnicka, Dorota
    Stelmach, Piotr
    Kupnicki, Piotr
    Szataniak, Magdalena
    Robak, Tadeusz
    ANNALS OF HEMATOLOGY, 2022, 101 (06) : 1387 - 1392
  • [6] Leukemia cutis in accelerated chronic lymphocytic leukemia: successful treatment with venetoclax and rituximab
    Ewa Robak
    Dorota Jesionek-Kupnicka
    Piotr Stelmach
    Piotr Kupnicki
    Magdalena Szataniak
    Tadeusz Robak
    Annals of Hematology, 2022, 101 : 1387 - 1392
  • [7] Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Treated with Fixed Duration Venetoclax-Rituximab: Assessment of Response with Ultrasound, and Relationship with Minimal Residual Disease
    Benedetti, Edoardo
    Barate, Claudia
    Mavilia, Fabrizio
    Bramanti, Emilia
    Morganti, Riccardo
    Guerri, Valentina
    Cervetti, Giulia
    Capochiani, Enrico
    Bertaggia, Ilaria
    Stella, Salvatore Massimo
    Traverso, Ginevra
    Bruno, Benedetto
    Galimberti, Sara
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (05)
  • [8] EXPERIENCE IN OUR CENTER WITH THE USE OF RITUXIMAB - VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKEMIA
    Pimentel, Villar Ma
    De Leon, Marcano E.
    Jimenez, Moreno M.
    Lopez, Marquez T. J.
    Almagro, Torres F.
    Lopez, Lopez J. A.
    HAEMATOLOGICA, 2020, 105 : 389 - 390
  • [9] The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia
    Vitale, Candida
    Ferrajoli, Alessandra
    EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (08) : 885 - 894
  • [10] Four-Year Analysis of the MURANO Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia
    Awan, Farrukh T.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 8 - 9
12345